Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, ClearBridge Investments International Growth ADR Strategy. This analysis is provided for institutional research purposes only and is not investment advice.
"ClearBridge's international growth strategy suffered as value dramatically outperformed growth by 900+ basis points in Q3. Despite underperformance, managers maintain conviction in their disciplined approach across secular, structural, and emerging growth companies."
The ClearBridge International Growth ADR Strategy underperformed during Q3 2023 as value stocks dramatically outperformed growth by over 900 basis points, driven by rising bond yields and a resilient U.S. economy. The MSCI EAFE Growth Index fell 8.64% while the Value Index gained 0.59%. Despite disappointing performance, the managers remain committed to their disciplined, valuation-driven approach across secular, structural, and emerging growth companies rather than chasing value leadership they view as fleeting. The team was active in repositioning, swapping Roche for AstraZeneca in pharmaceuticals, adding Argenx in biotechnology, and initiating SMC to capitalize on Japan's improved corporate environment. Key detractors included ASML, which despite being positioned for AI growth failed to benefit like U.S. counterparts, and luxury names like LVMH amid sector weakness. The managers believe their portfolio is well-positioned to deliver alpha as headwinds from restricted global liquidity and lower-quality leadership dissipate, with the growth selloff creating new opportunities.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High conviction evidenced by maintaining growth strategy despite significant underperformance, active repositioning with specific named positions and rationales, and explicit commitment to not reversing course. Multiple specific holdings discussed with clear investment theses, though some hedging language around timing of catalysts prevents a higher score.
Growth Outlook
The managers acknowledge a challenging economic environment both in the U.S. and overseas, with rising bond yields and narrow market breadth creating headwinds. However, they express confidence that current conditions are temporary and see opportunities emerging from the growth selloff.
Risk Appetite
The portfolio remains committed to growth positioning despite underperformance, with managers actively adding new positions and increasing allocations in areas they view as oversold. They are selectively deploying capital while maintaining their core growth strategy.
Capital Deployment
Moderate deployment activity with multiple new positions added (AstraZeneca, Argenx, SMC, Sandvik) and existing positions increased (Deutsche Boerse), while also exiting underperforming names. No specific cash level changes mentioned, but clear evidence of active capital rotation and selective additions.
Forward Guidance
Managers are actively evaluating new investment opportunities created by the growth selloff and increasing positions in areas they believe have been overdone to the downside. They express confidence in eventual alpha generation as headwinds dissipate.
Language Signal
Language is balanced between acknowledging current challenges and disappointment with performance while expressing confidence in positioning and future opportunities. Risk language around value outperformance is offset by opportunity language around growth prospects.
Perceived Risk
Moderate risk acknowledgment with discussion of challenging economic environment, rising yields, and narrow market breadth. Risks are identified and discussed but not characterized as systemic or extreme, with managers viewing current headwinds as temporary rather than structural.
Opportunity Density
Managers see selective opportunities emerging from the growth selloff, with multiples coming down meaningfully in areas like renewables, consumer staples, and luxury goods. They describe evaluating quite a few new investment opportunities, suggesting a reasonably rich opportunity set despite challenging conditions.
Time Horizon
Multi-year investment horizon evidenced by holding through short-term volatility, focus on companies with strong fundamentals rather than near-term catalysts, and explicit mention of some holdings being time-based with catalysts yet to materialize. AstraZeneca patent portfolio extends to 2030s, indicating long-term thinking.
